Secondary Thrombocytosis Medication

Updated: Dec 01, 2020
  • Author: Devapiran Jaishankar, MBBS; Chief Editor: Srikanth Nagalla, MD, MS, FACP  more...
  • Print

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications in cases of secondary thrombocytosis (reactive thrombocytosis).


Antiplatelet Agents

Class Summary

Antiplatelet agents inhibit platelet function by inhibition of the platelet cyclooxygenase system.

Aspirin (Anacin, Ascriptin, Bayer Aspirin)

Irreversibly acetylates (and inactivates) platelet and endothelial cell cyclooxygenase. A lower dose (65 mg) preferentially inhibits the platelet cyclooxygenase system (responsible for thromboxane A2 production) while preserving the beneficial effects of endothelial cell prostacyclin production due to difference in sensitivity to the inhibition by aspirin of cyclooxygenases at different sites and due to turnover of the endothelial cell cyclooxygenases.